NCT00017316View on ClinicalTrials.gov

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

September 30, 2003

Conditions
Melanoma (Skin)
Interventions
DRUG

semaxanib

DRUG

thalidomide

Trial Locations (1)

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00017316 - Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter